Sutro Biopharma Management
Management criteria checks 4/4
Sutro Biopharma's CEO is Bill Newell, appointed in Jan 2009, has a tenure of 15.33 years. total yearly compensation is $2.13M, comprised of 32.2% salary and 67.8% bonuses, including company stock and options. directly owns 0.41% of the company’s shares, worth $1.43M. The average tenure of the management team and the board of directors is 2.2 years and 4.9 years respectively.
Key information
Bill Newell
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 32.2% |
| CEO tenure | 15.3yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.2yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Aug 11Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M
Aug 08Sutro to get $10M payment from Merck after first patient dosed in collaboration trial
Jul 26Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Dec 27Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates
Jun 18Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts
May 09Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
May 07Sutro Biopharma EPS misses by $0.04, beats on revenue
May 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$687k | -US$107m |
| Sep 30 2023 | n/a | n/a | -US$172m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$130m |
| Dec 31 2022 | US$3m | US$663k | -US$119m |
| Sep 30 2022 | n/a | n/a | -US$123m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | -US$114m |
| Dec 31 2021 | US$6m | US$625k | -US$106m |
| Sep 30 2021 | n/a | n/a | -US$127m |
| Jun 30 2021 | n/a | n/a | -US$79m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$2m | US$554k | -US$32m |
| Sep 30 2020 | n/a | n/a | US$13m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$4m | US$497k | -US$56m |
| Sep 30 2019 | n/a | n/a | -US$42m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$38m |
| Dec 31 2018 | US$9m | US$482k | -US$35m |
| Sep 30 2018 | n/a | n/a | -US$49m |
| Jun 30 2018 | n/a | n/a | -US$40m |
| Mar 31 2018 | n/a | n/a | -US$30m |
| Dec 31 2017 | US$703k | US$468k | -US$20m |
Compensation vs Market: Bill's total compensation ($USD2.13M) is about average for companies of similar size in the US market ($USD2.43M).
Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.
CEO
Bill Newell (65 yo)
15.3yrs
Tenure
US$2,129,980
Compensation
Mr. William J. Newell, also known as Bill, J.D. has been the Chief Executive Officer and Director of Sutro Biopharma, Inc. since February 2009. He served as Independent Director at Vaxcyte, Inc. since Nove...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 15.3yrs | US$2.13m | 0.41% $ 1.4m | |
| Chief Scientific Officer | less than a year | US$1.63m | 0% $ 0 | |
| Chief Medical Officer | 1.3yrs | US$2.34m | 0.030% $ 103.6k | |
| President & COO | less than a year | US$1.43m | 0.052% $ 179.3k | |
| Founder | no data | no data | no data | |
| CFO & Secretary | 11.3yrs | US$2.08m | 0.13% $ 453.7k | |
| Chief Technical Operations Officer | less than a year | no data | 0.039% $ 134.9k | |
| General Counsel | 3.2yrs | no data | no data | |
| Chief People & Communications Officer | 16.3yrs | US$1.30m | 0.10% $ 354.2k | |
| Chief Portfolio Strategy & Alliance Officer | no data | no data | 0.017% $ 60.7k | |
| Vice President & Controller | no data | no data | no data |
2.2yrs
Average Tenure
60.5yo
Average Age
Experienced Management: STRO's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 15.3yrs | US$2.13m | 0.41% $ 1.4m | |
| Independent Chair of the Board | 4.9yrs | US$173.11k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$138.11k | 0% $ 0 | |
| Independent Director | 10.3yrs | US$138.11k | 0.069% $ 239.4k | |
| Independent Director | 14.8yrs | US$140.11k | 0.027% $ 95.5k | |
| Member of Scientific Advisory Board | 1.3yrs | US$1.53m | 0.12% $ 426.6k | |
| Chair of the Scientific Advisory Board | 4yrs | no data | no data | |
| Independent Director | 5.8yrs | US$133.11k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$152.11k | 0% $ 0 | |
| Co-Chair of Clinical Advisory Board & Member of Scientific Advisory Board | no data | no data | no data | |
| Member of the Clinical Advisory Board | 4yrs | no data | no data | |
| Independent Director | 2.5yrs | US$150.28k | 0% $ 0 |
4.9yrs
Average Tenure
65yo
Average Age
Experienced Board: STRO's board of directors are considered experienced (4.9 years average tenure).